Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-guided pazopanib dosing feasibility study in advanced solid tumors
NL-OMON40372Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pazopanib in Nonhematologic neoplasms, renal cell carcinoma (RCC) and soft tissue sarcoma (STS), sponsored by Netherlands Cancer Institute. Primary endpoint: Safety and feasibility of PK-guided pazopanib dosing. Started Sep 2013; status: recruiting.
02
Drugs
pazopanib
03
Conditions
Nonhematologic neoplasmsrenal cell carcinoma (RCC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON40372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40372.